中国神经再生研究(英文版)

中国神经再生研究(英文版) ›› 2024, Vol. 19 ›› Issue (9): 1877-1878.doi: 10.4103/1673-5374.391182

• 观点:退行性病与再生 • 上一篇    下一篇

阿尔茨海默病及其相关疾病的最新进展和未来治疗发展

  

  • 出版日期:2024-09-15 发布日期:2024-01-25

Recent advances and future therapy development for Alzheimer’s disease and related disorders

Megan Hong, Gal Bitan*   

  1. Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA (Hong M, Bitan G) 
    Department of Chemistry and Biochemistry, University of California Los Angeles, Los Angeles, CA, USA (Hong M)
    Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA, USA (Hong M, Bitan G) 
    Brain Research Institute, University of California, Los Angeles, CA, USA (Bitan G)
  • Online:2024-09-15 Published:2024-01-25
  • Contact: Gal Bitan, PhD, gbitan@mednet.ucla.edu.
  • Supported by:
    This work was supported by NIH grants RF1NS126406 and R21NS130326 and by a generous gift from the Binder Foundation (to GB).

PDF

42

摘要： https://orcid.org/0000-0001-7046-3754 (Gal Bitan)

Abstract: Over 55 million people globally live with Alzheimer’s disease (AD) or related dementias (ADRD) and the number is expected to double every twenty years. Until recently, only symptomatic treatments were available to patients with AD, including acetylcholine esterase inhibitors, of which the last one, galantamine, was approved by the US Food and Drug Administration (FDA) in 2001, and the noncompetitive N-methyl-D-aspartate receptor antagonist, memantine, approved in 2003. Thus, for nearly 20 years, despite numerous clinical trials, the landscape for developing new therapy looked barren and grim (Cummings et al., 2022). Then, in June 2021, FDA granted accelerated approval to aducanumab (AduhelmTM), an anti-amyloid-β (Aβ) monoclonal antibody (mAb) targeting “protofibrils”, which were described in the 1990s (Walsh et al., 1997) and shown later to be key neurotoxins. Aducanumab became the first approved drug addressing the underlying pathology of AD, albeit with substantial adverse effects. Due to the side effects and relatively weak efficacy data, the FDA approval was highly controversial (Kuller and Lopez, 2021): Ten of the eleven members of the scientific advisory committee voted against approval and the eleventh voted uncertain. Following the FDA’s decision, three committee members quit in protest.